impact factor
logo
 

One year in review

 

One year in review 2020: pathogenesis of primary Sjögren’s syndrome


1, 2, 3, 4, 5, 6, 7, 8, 9, 10

 

  1. Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK.
  2. Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Greece.
  3. Rheumatology Unit, Department of Clinical and Experimental Rheumatology, University of Pisa, Italy.
  4. Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK.
  5. Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK.
  6. Rheumatology Unit, Department of Clinical and Experimental Rheumatology, University of Pisa, Italy.
  7. Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK.
  8. Rheumatology Unit, Department of Clinical and Experimental Rheumatology, University of Pisa, Italy.
  9. Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Greece.
  10. Rheumatology Unit, Department of Clinical and Experimental Rheumatology, University of Pisa, Italy. chiara.baldini74@gmail.com

CER14026
2020 Vol.38, N°4 ,Suppl.126
PI 0003, PF 0009
One year in review

Free to view
(click on article PDF icon to read the article)

PMID: 33025887 [PubMed]

Received: 09/09/2020
Accepted : 16/09/2020
In Press: 29/09/2020
Published: 22/10/2020

Abstract

The pathogenesis of primary Sjögren’s syndrome (pSS) remains poorly understood. However, important efforts have been made during the last few months. In this review, following the others of this series we will summarise the most recent literature on pSS pathogenesis focusing in particular on new insights into pSS animal models, genetics and epigenetics, innate and adaptive immune system abnormalities and tertiary lymphoid structures. Hopefully, novel insights into pSS pathogenesis will pave the way to new therapeutic approaches to the disease improving patients’ management and prognosis.

Rheumatology Article